Accelerate to discover

Back to filter

Related topics

Standardize tumor sample preparation and reduce background with Curiox laminar wash system

Curiox

Aug 10, 2022

Laminar Wash technology offers a gentle alternative that can improve yield and data quality, particularly of rare cell...

Developing a 43 color panel on Cytek Aurora using Laminar Wash for sample prep

Curiox

Aug 2, 2022

Successfully executing a 43 color panel is a technically demanding task. One that is made more difficult when there are...

Intoducing spheroOne: Automated sorting and isolation of single spheroids and organoids

Cellenion

Jun 21, 2022

spheroONE is an innovative single large-particle sorter and dispenser which revolutionizes 3D cellular models handling....

Outstanding post-sort sample recovery on the WOLF Cell Sorter

NanoCellect

Jun 14, 2022

The new WOLF G2 instrument has significantly expanded the capabilities of gentle benchtop microfluidic cell sorting...

Aug 18, 2022

Incucyte AI module: Advanced Label-Free Classification Analysis

Sartorius & Essen BioScience

Jun 6, 2022

Monitor adherent cell morphology changes objectively to determine live/dead cell counts or classify cells based on...

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters

MOLECUBES

Jun 3, 2022

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine...

An experimental strategy for preparing circular ssDNA virus genomes for next-generation sequencing

Sage Science

Jun 1, 2022

Recent article from February 2022 shoes how size selection improved viral read mapping by over 90% for begomoviruses.

Aug 18, 2022

Intoducing cellenONE: The revolutionary Single Cell isolator

Cellenion

May 25, 2022

A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...

Show all topics (10)

Preclinical cardiac safety assesment

Mar 22, 2016

Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.

Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.

The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.

The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.

Application
Product news

Related technologies: Real-time, label free cell analysis

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Cardio Instrument is a high-resolution system for label-free-dual-mode monitoring of cardiomyocyte and cardiotoxicity testing

show detail

The new CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey